Edition:
United Kingdom

Achaogen Inc (AKAO.OQ)

AKAO.OQ on NASDAQ Stock Exchange Global Market

11.12USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$11.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
233,521
52-wk High
$27.78
52-wk Low
$10.24

Latest Key Developments (Source: Significant Developments)

Achaogen Appoints Blake Wise Chief Executive Officer
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Achaogen Inc ::ACHAOGEN APPOINTS BLAKE WISE CHIEF EXECUTIVE OFFICER.ACHAOGEN INC - KENNETH HILLAN TO BECOME PRESIDENT, RESEARCH AND DEVELOPMENT.ACHAOGEN INC - BLAKE WISE WILL SUCCEED KENNETH HILLAN, AS CHIEF EXECUTIVE OFFICER EFFECTIVE JANUARY 1, 2018.  Full Article

Achaogen reports Q3 loss per share $0.85
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Achaogen Inc ::Achaogen reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.85.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Achaogen - ‍unrestricted cash, cash equivalents and short-term investments totaled $199.4 million at Sept 30, 2017 compared to $145.9 million at Dec 31, 2016​.  Full Article

Achaogen submits Plazomicin new drug application to FDA
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Achaogen Inc :Achaogen submits Plazomicin new drug application (NDA) to the U.S. FDA for treatment of complicated urinary tract infections and bloodstream infections.Achaogen Inc - co also intends to submit an application for registration of Plazomicin​ in European Union in 2018.  Full Article

Achaogen reports Q2 2016 financial results and provides corporate update
Monday, 8 Aug 2016 

Achaogen Inc : Q2 loss per share $0.87 . Achaogen reports second quarter 2016 financial results and provides corporate update . Achaogen Inc says contract revenue totaled $9.1 million for Q2 of 2016 compared to $12.0 million for same period of 2015 .Q2 earnings per share view $-0.67, revenue view $5.7 million -- Thomson Reuters I/B/E/S.  Full Article

Achaogen updates on $25 mln financing
Tuesday, 14 Jun 2016 

Achaogen Inc : Achaogen Inc says it raised about $25 million through sale of certain securies that included equities - sec filing .Achaogen Inc made the disclosure about the financing via a form d filing with the u.s. Sec.  Full Article

Achaogen adds Tobin Schilke as chief financial officer
Friday, 3 Jun 2016 

Achaogen Inc : Achaogen adds Tobin Schilke as chief financial officer .Achaogen Inc says Schilke most recently served as CFO and company director of Roche Products Limited in United Kingdom.  Full Article

Achaogen reaches 50 pct enrollment in Phase 3 epic registration trial of plazomicin
Thursday, 2 Jun 2016 

Achaogen Inc : Achaogen reaches 50 percent patient enrollment in Phase 3 epic registration trial of plazomicin . Look forward to completing enrollment in epic trial this year and expect to report top-line data in Q1 of 2017 . Expects to announce top-line results for care study, Phase 3 clinical trial in patients with serious bacterial infections due to CRE, in H1 2017 .Epic trial is expected to serve as a single pivotal trial and support a new drug application (NDA) submission in second half of 2017.  Full Article

Achaogen awarded $2.4 million contract option by NIAID
Thursday, 21 Apr 2016 

Achaogen:Awarded an additional $2.4 million under an existing contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services.The award will fund the continued research and development of Achaogen's LpxC inhibitors, which are novel small molecule agents for the potential treatment of bacterial infections, including those resistant to currently available antibiotics.NIAID funding for the LpxC inhibitor research program now totals $4.4 million and, should the remaining contract option be exercised, the total award would reach $5 million.  Full Article

BRIEF-Achaogen Appoints Blake Wise Chief Executive Officer

* ACHAOGEN INC - KENNETH HILLAN TO BECOME PRESIDENT, RESEARCH AND DEVELOPMENT